Autolus Therapeutics Stock (NASDAQ:AUTL)
Previous Close
$3.01
52W Range
$2.94 - $7.45
50D Avg
$3.92
200D Avg
$4.53
Market Cap
$895.61M
Avg Vol (3M)
$1.21M
Beta
2.04
Div Yield
-
AUTL Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| VECT | VectivBio Holding AG |
| IKNA | Ikena Oncology, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| MNOV | MediciNova, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |